BR0113169A - Composição farmacêutica compreendendo composto de indol condensado - Google Patents

Composição farmacêutica compreendendo composto de indol condensado

Info

Publication number
BR0113169A
BR0113169A BR0113169-9A BR0113169A BR0113169A BR 0113169 A BR0113169 A BR 0113169A BR 0113169 A BR0113169 A BR 0113169A BR 0113169 A BR0113169 A BR 0113169A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
indole compound
salt
condensed indole
Prior art date
Application number
BR0113169-9A
Other languages
English (en)
Inventor
Philip Christopher Buxton
Dirk Marinus Johannes Va Schie
Seona Thomson
Original Assignee
Smithkline Beecham Plc
Glaxosmithkline Lab Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0019524A external-priority patent/GB0019524D0/en
Priority claimed from GB0118919A external-priority patent/GB0118919D0/en
Priority claimed from GB0119022A external-priority patent/GB0119022D0/en
Priority claimed from PCT/GB2001/003544 external-priority patent/WO2002011766A2/en
Application filed by Smithkline Beecham Plc, Glaxosmithkline Lab Sas filed Critical Smithkline Beecham Plc
Priority claimed from PCT/GB2001/003590 external-priority patent/WO2002011733A1/en
Publication of BR0113169A publication Critical patent/BR0113169A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA COMPREENDENDO COMPOSTO DE INDOL CONDENSADO". Trata-se de uma composição farmacêutica compreendendo N- [(1-^ n^butil-4-piperidinil)metil] -3,4-diidro-2H-[1,3]oxazino[3,2-a]indol-10-carboxamida (SB 207266) ou um seu sal farmaceuticamente aceitável em combinação com um ou mais veículos farmaceuticamente aceitáveis, onde pelo menos parte do SB 207266 ou seu sal está em forma granulada. Preferivelmente, uma carga e/ou aglutinante estão também presentes.
BR0113169-9A 2000-08-08 2001-08-08 Composição farmacêutica compreendendo composto de indol condensado BR0113169A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0019524A GB0019524D0 (en) 2000-08-08 2000-08-08 Novel use
GB0118919A GB0118919D0 (en) 2001-08-02 2001-08-02 Novel use
GB0119022A GB0119022D0 (en) 2001-08-03 2001-08-03 Novel use
PCT/GB2001/003544 WO2002011766A2 (en) 2000-08-07 2001-08-07 Use of 5ht4 receptor antagonists in the manufacture of a medicament for the prophylaxis or treatment of atrial fibrillation
PCT/GB2001/003590 WO2002011733A1 (en) 2000-08-08 2001-08-08 Pharmaceutical composition comprising condensed indole compound

Publications (1)

Publication Number Publication Date
BR0113169A true BR0113169A (pt) 2003-07-15

Family

ID=27255838

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0113169-9A BR0113169A (pt) 2000-08-08 2001-08-08 Composição farmacêutica compreendendo composto de indol condensado

Country Status (12)

Country Link
US (3) US20030032640A1 (pt)
EP (2) EP1872785A1 (pt)
JP (1) JP2008247915A (pt)
KR (1) KR100896563B1 (pt)
CN (2) CN1679583A (pt)
AT (1) ATE374027T1 (pt)
BR (1) BR0113169A (pt)
CY (1) CY1107836T1 (pt)
HK (1) HK1056998A1 (pt)
MX (1) MXPA03001207A (pt)
NZ (1) NZ535261A (pt)
PT (1) PT1313481E (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL365048A1 (en) * 2000-08-07 2004-12-27 Laboratoire Glaxosmithkline S.A.S. Use of 5ht4 receptor antagonists in the manufacture of a medicament for the prophylaxis or treatment of atrial fibrillation
DK1476136T3 (da) * 2002-02-14 2006-10-09 Glaxo Group Ltd Farmaceutisk præparat, der omfatter N-[(1-N-butyl-4-piperidinyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indol-10-carboxamid eller salt, og fremgangsmåde derfor, der omfatter törgranulering
GB0211230D0 (en) * 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
EP2397161B1 (en) * 2009-02-12 2019-09-25 Fuji Chemical Industry Co., Ltd. Disintegrating particle composition and rapidly disintegrating compression-molded material comprising same
TW201129386A (en) * 2009-11-05 2011-09-01 Fmc Corp Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients
WO2014200347A1 (en) * 2013-06-14 2014-12-18 Ferring B.V. Extended release nicotinamide formulation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3134719A (en) * 1962-04-05 1964-05-26 American Cyanamid Co Calcium phosphates in tablet compressing
US5066441A (en) * 1980-12-12 1991-11-19 Rhone-Poulenc Basic Chemicals Co. Process for compacting a calcium phosphate composition
US4597969A (en) * 1982-04-05 1986-07-01 Merck Sharp & Dohme Stabilization of unstable drugs or food supplements
DE3332830A1 (de) * 1982-09-16 1984-03-22 The Upjohn Co., 49001 Kalamazoo, Mich. Verwendung von benzodiazepinen zur bekaempfung oder bei der behandlung von panikzustaenden
US4569852A (en) * 1983-08-23 1986-02-11 Warner-Lambert Company Maintenance of flavor intensity in pressed tablets
US4713245A (en) * 1984-06-04 1987-12-15 Mitsui Toatsu Chemicals, Incorporated Granule containing physiologically-active substance, method for preparing same and use thereof
US5055307A (en) * 1988-12-29 1991-10-08 Asahi Kagaku Kogyo Kabushiki Kaisha Slow release drug delivery granules and process for production thereof
US5852014A (en) * 1992-03-12 1998-12-22 Smithkline Beecham P.L.C. Condensed indole derivatives as 5HT4 -receptor antagonists
ES2132223T3 (es) * 1992-03-12 1999-08-16 Smithkline Beecham Plc Derivados de indol condensados en calidad de antagonistas del receptor 5-ht4.
US5998409A (en) * 1992-03-12 1999-12-07 Smithkline Beecham Plc Condensed indole derivatives as 5HT4 -receptor antagonists
DE4418837A1 (de) * 1994-05-30 1995-12-07 Bayer Ag Thermisches Granulierverfahren
FR2740357B1 (fr) * 1995-10-25 1997-11-28 Rhone Poulenc Chimie Granules redispersables dans l'eau comprenant une matiere active sous forme liquide et un tensio-actif non ionique du type alcoxyles
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
US6660298B1 (en) * 2000-07-27 2003-12-09 Pentech Pharmaceuticals, Inc. Paroxetine tablets and capsules

Also Published As

Publication number Publication date
US20060057218A1 (en) 2006-03-16
ATE374027T1 (de) 2007-10-15
CN1268340C (zh) 2006-08-09
MXPA03001207A (es) 2004-08-12
NZ535261A (en) 2004-12-24
PT1313481E (pt) 2008-01-02
US20030032640A1 (en) 2003-02-13
KR100896563B1 (ko) 2009-05-07
US20050148582A1 (en) 2005-07-07
EP1867333A1 (en) 2007-12-19
EP1872785A1 (en) 2008-01-02
CY1107836T1 (el) 2013-06-19
CN1679583A (zh) 2005-10-12
CN1458845A (zh) 2003-11-26
JP2008247915A (ja) 2008-10-16
KR20030023745A (ko) 2003-03-19
HK1056998A1 (en) 2004-03-12

Similar Documents

Publication Publication Date Title
CY1107836T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει ενωση συμπυκνωμενης ινδολης
HUP9900717A2 (hu) Szilárd dezodoráló készítmény
UA66952C2 (uk) N-(5,7-диметокси[1,2,4]триазоло[1,5-a]піримідин-2-іл)арилсульфонамід, спосіб його одержання, композиція на його основі та спосіб боротьби з небажаною рослинністю
CA2370147A1 (en) Piperidine-indole compounds having 5-ht6 affinity
NO20006039D0 (no) Fremgangsmåte for fremstilling av 4-karboksyamino-2- substituert-1,2,3,4- tetrahydroquinolin
WO2002024685A8 (fr) Derives de l'indole et leur utilisation en tant qu'agents antifongiques et/ou antiparasitaires
DZ2700A1 (fr) Indoles 2,3-substitués servant d'agents anti-inflammatoires et analgésiques.
WO2000058307A3 (en) Aryl fused 2,4-disubstituted pyridines: nk3 receptor ligands
PT1476136E (pt) Composicao farmaceutica compreendendo n-((1-n-butil-4-piperidinil)metil)-3,4-di-hidro-2h-(1,3) oxazino (3,2-a) indole-10-carboxamida ou sal e processo de a obter compreendendo granulacao a seco.
DK0966277T3 (da) Anvendelse af R-NSAID'er til forebyggelse af Alzheimer's sygdom
AU4316301A (en) Novel 2,3,4,5-tetrahydro-1H-(1,4)diazepino(1,7a)indole compounds
EA200100089A1 (ru) Предотвращение рецидива мигрени
CA2268399A1 (en) Anti-neurogenic inflammatory compounds and compositions and methods of use thereof
AU1054500A (en) N-substituted (3,6-dihydro)-2h-1,2-oxazine derivatives, their preparation and their use as selective mglur1 antagonists
NO20000456D0 (no) Fremgangsmåte for fremstilling av 1,2-dikloretan
NO20002408D0 (no) 5-HT1F antagonister
EE200000619A (et) Oktahüdro-6,10-diokso-6H-püridasino[1,2-a][1,2]diasepiin-1-karboksüülhappe derivaadid, nende ratseemiline segu, valmistamismeetod ja kasutamine ning vaheühendid
HUP9900883A3 (en) Amino acid derivatives of substituted quinoxaline 2,3-dione derivatives as glutamate receptor antagonists
CA2264549A1 (en) Spirocyclic dopamine receptor subtype ligands
ES2174573T3 (es) Procedimientos de identificacion de substancias para la inhibicion de las lesiones neoplasticas.
ZA974930B (en) Amide derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists.
PT1033132E (pt) Composicao de farmaco rapidamente soluvel
HUP9702475A3 (en) Quinoline, isoquinoline, quinazoline, benzoxazine derivatives substituted with sulfonamide group, process for production thereof and pharmaceutical compositions containing them
CA2418921A1 (en) Novel composition
NO20005743L (no) Fremgangsmåte til fremstilling av 4,5-epoksymorfinan-6- glukuronider

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: SMITHKLINE BEECHAM P.L.C. (GB)

Free format text: TRANSFERIDO DE: LABORATOIRE GLAXOSMITHKLINE S.A.S.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.